Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer

Most advanced-stage ovarian cancer patients, including those with epithelial ovarian cancer (EOC), develop recurrent disease and acquisition of resistance to chemotherapy, leading to limited treatment options. Decrease in Let7b miRNA levels in clinical ovarian cancer has been associated with chemore...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandham, Srujan K., Rao, Mounika, Shah, Aayushi, Trivedi, Malav S., Amiji, Mansoor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971728/
https://www.ncbi.nlm.nih.gov/pubmed/35399604
http://dx.doi.org/10.1016/j.omto.2022.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971728/
https://www.ncbi.nlm.nih.gov/pubmed/35399604
http://dx.doi.org/10.1016/j.omto.2022.03.005

Ejemplares similares